Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;95(2):212-215.
doi: 10.1016/j.diagmicrobio.2019.05.001. Epub 2019 May 8.

Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017

James A Karlowsky  1 , Sibylle H Lob  2 , Katherine Young  3 , Mary R Motyl  3 , Daniel F Sahm  4
Affiliations

Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017

James A Karlowsky et al. Diagn Microbiol Infect Dis. 2019 Oct.

Abstract

A total of 2732 isolates of Pseudomonas aeruginosa collected at 26 United States clinical laboratories in 2015-2017 were tested for susceptibility to imipenem-relebactam. Imipenem-relebactam MICs were interpreted using 2018 CLSI M100 imipenem breakpoints for P. aeruginosa. A total of 93.9% of P. aeruginosa isolates were susceptible to imipenem-relebactam. Among MDR isolates (n = 750), susceptibility to imipenem-relebactam was 79.7%, 46-73 percentage points higher than to other β-lactams tested. Relebactam restored imipenem susceptibility to 78.3% of imipenem-nonsusceptible isolates (n = 766) and to 69.6% of imipenem-nonsusceptible isolates with MDR phenotypes (n = 500).

Keywords: Imipenem-relebactam; Multidrug-resistance; Pseudomonas aeruginosa; SMART; Surveillance; United States.

PubMed Disclaimer

MeSH terms

LinkOut - more resources